TICKERNERD
Menu
NVCTNVCTHealthcare · Biotechnology

NVCT Stock Forecast: Nuvectis Pharma, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$24
+6.67% on the day

The 6 Wall Street analysts covering Nuvectis Pharma, Inc. hold a median 12-month price target of $35 — +45.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 10 Sept 2026 — in the upper half.

Market cap
$734.2M
Ticker Nerd rank
67 / 100
Median analyst target
$35
Analysts covering
6
Revenue$0.0
Operating income−$7.2M
Net income−$7.0M
Free cash flow−$4.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
+23.6%
YTD
+217.7%
1Y
+268.5%
From 52W high
−15.9%
From 52W low
+324.6%
$6
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nuvectis Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Volatility
91
Value
90
Accruals
77
Revisions
52
Size
49
Issuance
38
Growth
30
Quality
26

Momentum (92): The shares have been drifting up relative to others.

Quality (26): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26NVCTHigh $40Median $35Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $30Median $35High $40

The green dot is the last close — the median target sits +45.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026Cantor FitzgeraldInitiatesOverweight—
6 July 2026Roth CapitalMaintainsBuy$20 → $33
6 July 2026Roth CapitalMaintainsBuy—
22 June 2026HC Wainwright & Co.MaintainsBuy—
12 June 2026HC Wainwright & Co.MaintainsBuy—
4 Aug 2025HC Wainwright & Co.MaintainsBuy—
30 Apr 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025Maxim GroupInitiatesBuy—
17 Mar 2025Laidlaw & Co.InitiatesBuy—
25 Feb 2025HC Wainwright & Co.MaintainsBuy—
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
15 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy—
10 Feb 2023HC Wainwright & Co.ReiteratesBuy—
13 July 2022Ladenburg ThalmannInitiatesBuy—
10 May 2022HC Wainwright & Co.MaintainsBuy—
2 Mar 2022HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NVCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Nuvectis Pharma, Inc. returned +268.5% against +17.5% for the S&P 500, dividends included.

NVCT vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Oct 25Jan 26Apr 26Jul 26NVCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NVCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Nuvectis Pharma, Inc. (NVCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−17.9×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
69.6×

Cheaper than 2% of US stocks

EV / EBITDA
−25.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−214.6%

Higher than 7% of US stocks

Return on assets
−73.1%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nuvectis Pharma, Inc. (NVCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nuvectis Pharma, Inc. has a market value of $734.2M and an enterprise value of $710.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$27.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$19.5M.

  • Shares outstanding: 26.7M.

  • Trailing P/E: −17.9×; forward P/E: −24.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Nuvectis Pharma, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

NVCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NVCTNuvectis Pharma, Inc.$734.2M
67
ZVRAZevra Therapeutics, Inc.$708.1M
98
CBIOCrescent Biopharma, Inc.$719.2M
57
NGNENeurogene, Inc.$697.2M
60
AURAAura Biosciences, Inc.$722.7M
41
CTMXCytomX Therapeutics, Inc.$724.2M
47
MPLTMapLight Therapeutics, Inc.$728.5M
12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nuvectis Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVCT news & analysis

Nuvectis Pharma To Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Nuvectis Pharma announced that senior management will participate in the 2026 Cantor Global Healthcare Conference, including a fireside chat scheduled for Friday, September 11, 2026 at 9:10 AM ET. The announcement was made by the company on September 3, 2026.

Why it matters — A NVCT watcher would care because senior management's participation in investor conferences gives investors an opportunity to hear directly from company leadership about its clinical-stage programs.

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

Zacks Investment Research · 19 Aug 2026positive

Nuvectis Pharma's stock rose roughly 97% over three months, a gain attributed to optimism surrounding its expanding pipeline, including the NXP100 and NXP200 programs as new value drivers.

Why it matters — NVCT watchers would care because the surge reflects growing market confidence in the company's pipeline expansion beyond its existing programs.

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire · 4 Aug 2026neutral

Nuvectis Pharma, a clinical-stage biopharmaceutical company developing therapies for complement-related conditions and oncology, reported its financial results for the second quarter of 2026 and provided an update on recent business progress. The announcement was made via press release on August 4, 2026.

Why it matters — A quarterly financial and business update provides NVCT watchers with the company's latest operational and financial status.

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

Zacks Investment Research · 29 July 2026positive

The mean of analysts' price targets for Nuvectis Pharma points to a 56.4% upside in the stock. Strong agreement among analysts in raising earnings estimates suggests an upside for the stock.

Why it matters — NVCT watchers would care because analyst price targets and upward earnings estimate revisions can signal positive expectations for the stock.

FAQ

Frequently asked questions about NVCT stock

What is the NVCT stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Nuvectis Pharma, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVCT stock a buy right now?

Of the 6 analysts covering Nuvectis Pharma, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvectis Pharma, Inc. 67 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVCT?

As at 10 Sept 2026, Nuvectis Pharma, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will NVCT stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +45.9% from the last close, and Ticker Nerd's factor model ranks Nuvectis Pharma, Inc. 67 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVCT stock forecast for 2030?

No analyst covering Nuvectis Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.

How has NVCT stock performed over the past year?

Nuvectis Pharma, Inc. returned +268.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuvectis Pharma, Inc. do?

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need.

What is the latest news on NVCT?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Nuvectis Pharma To Participate in Upcoming Investor Conferences". Nuvectis Pharma announced that senior management will participate in the 2026 Cantor Global Healthcare Conference, including a fireside chat scheduled for Friday, September 11, 2026 at 9:10 AM ET. The announcement was made by the company on September 3, 2026.

Company

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need. The company works on targeted small-molecule therapies designed for genetically defined cancer patient populations, with its current pipeline centered on NXP800 and NXP900. NXP800 is being developed for specific ovarian cancer settings, while NXP900 is designed to inhibit SRC family kinases, including SRC and YES1, in solid tumors. Based in Fort Lee, New Jersey, Nuvectis Pharma operates as a single-segment biotechnology business centered on oncology drug development and clinical research.

CEO Mr. Ron Bentsur M.B.A. · 16 employees · United States · https://www.nuvectis.com